Colorectal Cancer and the Role of Endoscopic Submucosal Dissection (ESD): A Cognitive Recovery Perspective
Colorectal cancer stands as a global health challenge, ranking third in cancer incidence and second in cancer-related deaths, with 1.9 million new cases and 930,000 fatalities reported in 2020. Projections indicate a doubling of cases by 2040, underscoring the critical need for early detection and intervention. Endoscopic submucosal dissection (ESD) has emerged as a preferred technique for removing precancerous lesions, offering superior outcomes compared to conventional methods. However, the complexity of ESD procedures often necessitates prolonged deep sedation, raising concerns about patient safety, particularly regarding cognitive recovery post-procedure. But here's where it gets controversial: while propofol remains the sedative of choice due to its rapid onset and recovery, its dose-dependent cardiovascular effects may compromise cerebral perfusion, potentially impacting cognitive function. Recent studies have highlighted incomplete cognitive recovery in a significant percentage of patients, sparking debates about the safety of endoscopic sedation.
The Lidocaine Solution: A Neuroprotective Adjuvant?
Intravenous lidocaine has been proposed as a solution to mitigate propofol-related complications, including reducing propofol consumption and eliminating injection pain. Systematic reviews suggest lidocaine’s potential in reducing postoperative cognitive dysfunction, attributed to its anti-inflammatory and neuroprotective properties. However, results across trials are inconsistent, with some studies reporting cognitive benefits and others finding no significant effects. And this is the part most people miss: the cognitive effects of lidocaine during endoscopic procedures, where sedation and hemodynamic profiles differ from general anesthesia, remain largely unexplored. This gap in knowledge prompted our randomized controlled trial to investigate lidocaine’s impact on cognitive recovery following ESD.
Trial Design and Key Findings
Our study, conducted at the Gastrointestinal Endoscopy Center of Fujian Provincial Hospital, enrolled 234 patients undergoing colorectal ESD. Participants were randomized to receive either intravenous lidocaine or placebo, with cognitive recovery assessed on postoperative day 3 using the PostopQRS cognitive domain. The results were striking: the lidocaine group demonstrated significantly higher cognitive recovery rates (92.3% vs. 80.3% in the placebo group). Secondary outcomes, including reduced propofol consumption, shorter emergence times, and lower injection pain scores, further supported lidocaine’s benefits. Safety profiles were comparable, with lidocaine showing a reduced incidence of hypotension.
Implications and Future Directions
Our findings suggest that intravenous lidocaine enhances cognitive recovery and procedural outcomes in ESD, positioning it as a valuable adjuvant in endoscopic sedation. However, the study’s limitations, including exclusion criteria that limit generalizability and the absence of long-term cognitive follow-up, warrant caution. Future research should focus on multicenter trials involving high-risk populations, dose-response evaluations, and the integration of biomarkers and neuroimaging to elucidate lidocaine’s neuroprotective mechanisms. Thought-provoking question: Can lidocaine’s cognitive benefits be consistently replicated across diverse surgical contexts, or are they specific to the unique hemodynamic and sedative profiles of endoscopic procedures? The debate continues, inviting further exploration and discussion in the medical community.
